Linagliptin-metformin (Jentadueto - Boehringer Ingelheim (Canada) Ltd.) indication: type 2 diabetes mellitus
CADTH
Record ID 32014000876
English
Authors' recommendations:
The Canadian Drug Expert Committee (CDEC) recommends that linagliptin/metformin (Jentadueto) be listed for patients if the following clinical criterion is met:
Patients for whom insulin is not an option and who are already stabilized on therapy with metformin, a sulfonylurea and linagliptin, to replace the individual components of linagliptin and metformin for these patients.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.cadth.ca/media/cdr/complete/cdr_complete_Jentadueto_October-21-13_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Diabetes Mellitus, Type 2
- Metformin
- Drug Therapy, Combination
- Dipeptidyl-Peptidase IV Inhibitors
- Hypoglycemic Agents
- Linagliptin
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.